Bone density and metabolism in thalassaemia

Journal of Pediatric Endocrinology and Metabolism

Volumn 11, Issue SUPPL. 3, 1998, Pages 785-790

  Lala, R ^a   Chiabotto, P ^a   Di Stefano, M ^b   Isaia, G C ^b   Garofalo, F ^c   Piga, A ^c  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; DEFERIPRONE; DEFEROXAMINE; OSTEOCALCIN; PYRIDINOLINE;

ADOLESCENT; BONE AGE; BONE DENSITY; BONE MARROW; BONE METABOLISM; CHELATION THERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GROWTH DISORDER; HUMAN; HYPERPLASIA; LUMBAR SPINE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; SCHOOL CHILD; THALASSEMIA;

ADOLESCENT; AGE DETERMINATION BY SKELETON; AMINO ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; BODY HEIGHT; BONE DENSITY; CHILD; COLLAGEN; COLLAGEN TYPE I; DEFEROXAMINE; DENSITOMETRY, X-RAY; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; PYRIDONES;

EID: 0032441175     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Orvieto R, Leichter I, Rachmilewitz A, Margulies JY. Bone density, mineral content, and cortical index in patients with thalassaemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcif Tissue Int 1992; 50: 397-399.
2. Giuzio E, Bria M, Brancati C. Le alterazioni scheletriche nella thalassemia major. GIOT 199 ; 17: 277-283.
3. Filosa A, Di Maio S, Vocca S, Saviano A, Esposito G, Pagano L. Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis. Acta Paediatr 1997; 86: 342-346.
4. Gowin W, Felsenberg D. Methods in osteodensitometry. In: Schonau E, ed. Pediatric Osteology - New Developments in Diagnostic and Therapy. Amsterdam-Lausanne-New York-Oxford-Shannon-Tokyo: Elsevier, 1996; 73-81.
5. Acil Y, Muller PK. Rapid method for the isolation of mature collagen cross-links, hydroxylysylpyridinoline and lysylpyridinoline. J Chromatogr A 1994; 664: 183-188.
6. Risteli J, Elomaa J, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen. A new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-640.
7. Price PA, Parthermore JG, Deftos LJ. New biochemical marker of bone metabolism. Measurement by radioimmunoassay of bone Gla protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980; 66: 878-883.
8. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I collagen. Clin Chem 1990; 36: 1328-1330.
9. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children. Arch Dis Child 1966; 41: 613-635.
10. Pootrakul P, Hungsprenges S, Fucharoen S, Baylink D, Thompson E, English E, Lee M, Burnell J, Finch C. Relation between erythropoiesis and bone metabolism in thalassemia. N Engl J Med 1981; 24: 1470-1473.
11. Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, Bailey JD, Reilly BJ. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992; 14: 48-56.
12. Anapliotou MLG, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol 1995; 42: 279-287.
13. Levin TL, Sheth SS, Ruzal-Shapiro C, Abramson S, Piomelli S, Berdon WF. MRI marrow observations in thalassemia: the effects of the primary disease, transfusional therapy, and chelation. Pediatr Radiol 1995; 25: 607-613.